Key Takeaways
- The strongest oral prescription weight-loss pill currently available in the United States is phentermine/topiramate (Qsymia), which produces 9 to 11% body-weight loss at the highest dose over 56 weeks.
- Among single-agent pills, phentermine alone is the most weight-effective in the short term (4 to 6% loss at 12 to 24 weeks) but is restricted to 12 weeks of continuous use under FDA labeling.
- Naltrexone/bupropion (Contrave) produces 5 to 9% body-weight loss over 56 weeks, less than Qsymia but with a different side effect profile.
- Orlistat (Xenical, Alli) produces 3 to 4% weight loss but is the only OTC option (low dose) and is usable long-term.
- Oral semaglutide (Rybelsus) is approved for type 2 diabetes and produces about 4% weight loss at the 14 mg dose, less than its injectable counterparts.
- Injectable GLP-1 medications outperform every oral option: semaglutide injection (Wegovy) produces about 15% loss; tirzepatide injection (Zepbound) produces about 22% loss in published trials.
Direct answer (40-60 words)
The strongest oral prescription weight-loss pill is phentermine/topiramate (Qsymia), which produced 9 to 11% body-weight loss at the highest dose in the CONQUER and EQUIP trials. Among injectable medications, tirzepatide (Zepbound) is the strongest weight-loss prescription overall, producing 22.5% body-weight loss in SURMOUNT-1, but it is not a pill.
Table of contents
- The 30-second answer
- The honest definition of "strongest"
- The five FDA-approved oral weight-loss medications
- Phentermine/topiramate (Qsymia): the strongest pill
- Naltrexone/bupropion (Contrave)
- Phentermine alone (Adipex-P, Lomaira)
- Orlistat (Xenical, Alli)
- Oral semaglutide (Rybelsus)
- Why injectable GLP-1s outperform every pill
- How to compare strength fairly
- Side effects and contraindications by drug
- Who is and isn't a candidate for the stronger options
- FAQ
- Sources
- Footer disclaimers
The honest definition of "strongest"
"Strongest" is a fuzzy word in medicine. For weight-loss medications, it usually maps to one of three things:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Largest average percent body weight loss in randomized clinical trials at the highest approved dose
- Largest proportion of patients reaching meaningful weight loss thresholds (5%, 10%, 15% loss) within a year
- Magnitude of effect on appetite, food noise, or eating behavior as reported by patients
The first definition is the cleanest because it comes from controlled trial data with the same outcome measure. This article uses that definition and ranks oral medications by 56-week percent body weight loss in placebo-controlled trials.
The second and third definitions matter clinically too. A medication that produces strong appetite suppression but smaller percent weight loss may feel "stronger" to a patient. A medication that gets twice as many patients past the 10% threshold has a different real-world value than one with the same average loss but more variability.
For a definitive ranking, the published trial data are the starting point. Individual response varies.
The five FDA-approved oral weight-loss medications
The current FDA-approved oral medications for chronic weight management:
| Medication | Brand | Active ingredients | FDA approval | Avg weight loss at 1 year |
|---|---|---|---|---|
| Phentermine/topiramate ER | Qsymia | Phentermine + topiramate | 2012 | 9 to 11% (top dose) |
| Naltrexone/bupropion ER | Contrave | Naltrexone + bupropion | 2014 | 5 to 9% |
| Phentermine | Adipex-P, Lomaira | Phentermine | 1959 | 4 to 6% (12 weeks) |
| Orlistat | Xenical (Rx), Alli (OTC) | Orlistat | 1999 | 3 to 4% |
| Oral semaglutide | Rybelsus | Semaglutide (oral form) | 2019 (T2D only) | About 4% (off-label) |
Phentermine has been on the market since 1959 and is the oldest. Phentermine/topiramate ER is currently the strongest by published average weight loss. Rybelsus is included because it is sometimes prescribed off-label for weight loss, but it is FDA-approved only for type 2 diabetes.
A few medications were on the market and were withdrawn: lorcaserin (Belviq) was withdrawn in 2020 over cancer concerns. Sibutramine (Meridia) was withdrawn in 2010 over cardiovascular risk. Fen-phen was withdrawn in 1997 over heart valve damage.
Phentermine/topiramate (Qsymia): the strongest pill
Qsymia combines two existing drugs in a single extended-release capsule:
- Phentermine (a sympathomimetic amine that suppresses appetite, similar in mechanism to amphetamines but milder)
- Topiramate (an anti-seizure medication that has weight loss as a side effect, mechanism partly through GABA modulation and partly through carbonic anhydrase inhibition)
The fixed-dose combination steps:
- 3.75 mg phentermine / 23 mg topiramate (starter)
- 7.5 mg / 46 mg (low maintenance)
- 11.25 mg / 69 mg (mid)
- 15 mg / 92 mg (top)
The phase 3 trials were CONQUER (Gadde et al., Lancet, 2011) and EQUIP (Allison et al., Obesity, 2012). At the 15 mg/92 mg top dose over 56 weeks:
- Average weight loss: 9.8 to 10.9% of baseline body weight
- 67% of patients achieved at least 5% loss
- 47% of patients achieved at least 10% loss
The most common side effects are paresthesia (tingling, especially fingers and feet, 14 to 21%), dizziness (8 to 9%), dysgeusia (altered taste, 7 to 9%), insomnia (8 to 9%), constipation (15 to 16%), and dry mouth (14 to 21%). Topiramate also carries a small but real risk of cognitive slowing, kidney stones, and metabolic acidosis at higher doses.
Qsymia is contraindicated in pregnancy (topiramate is teratogenic; the REMS program requires negative pregnancy testing before starting and monthly during treatment in patients of reproductive potential), uncontrolled hypertension, hyperthyroidism, glaucoma, and recent MAOI use.
For an oral medication, this is currently the strongest option in the United States.
Naltrexone/bupropion (Contrave)
Contrave combines:
- Naltrexone (an opioid receptor antagonist; mechanism in obesity is thought to involve disrupting reward signaling around food)
- Bupropion (a norepinephrine and dopamine reuptake inhibitor used as an antidepressant, with weight loss as a side effect)
The maintenance dose is 2 pills twice daily (32 mg naltrexone / 360 mg bupropion total).
The phase 3 COR (Contrave Obesity Research) trials at 56 weeks (Greenway et al., Lancet, 2010; Apovian et al., Obesity, 2013):
- Average weight loss: 5 to 9% of baseline
- 42 to 48% of patients achieved at least 5% loss
- 18 to 25% of patients achieved at least 10% loss
Common side effects are nausea (32%), constipation (19%), headache (18%), vomiting (11%), and dizziness (10%). Contrave carries a black box warning for suicidal thoughts and is contraindicated in patients with seizure disorders, eating disorders, chronic opioid use, or uncontrolled hypertension.
Contrave is less weight-effective than Qsymia in head-to-head trial comparisons but offers an alternative for patients who can't take topiramate (e.g., women planning pregnancy near-term, patients with glaucoma).
Phentermine alone (Adipex-P, Lomaira)
Phentermine is a sympathomimetic amine, structurally similar to amphetamines but with milder CNS effects. It works by stimulating the release of norepinephrine in the hypothalamus, which suppresses appetite.
Standard dosing:
- Adipex-P: 37.5 mg once daily before breakfast (or 18.75 mg twice daily)
- Lomaira: 8 mg three times daily before meals
- Phentermine HCl 30 mg once daily
The label restricts continuous use to a maximum of 12 weeks because long-term safety data are limited and tolerance can develop. In practice, many providers prescribe phentermine for longer periods off-label, sometimes cyclically, sometimes continuously, with monitoring.
Short-term weight loss data:
- Average loss at 12 weeks: 4 to 6% of baseline body weight
- Larger losses at 24 weeks if used continuously off-label
Side effects include increased blood pressure and heart rate, insomnia, dry mouth, constipation, anxiety, and tremor. Phentermine is a Schedule IV controlled substance under the federal Controlled Substances Act.
It is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, history of substance abuse, and pregnancy.
Phentermine alone is "strong" in the sense that the appetite-suppressant effect is direct and rapid. It is weaker than Qsymia or Contrave for sustained 1-year weight loss because of the 12-week label limit and the tendency for tolerance.
Orlistat (Xenical, Alli)
Orlistat works through a different mechanism than the others. It's a pancreatic lipase inhibitor that blocks absorption of about 30% of dietary fat in the gut. Unabsorbed fat passes into the stool.
Doses:
- Xenical (prescription): 120 mg three times daily with meals
- Alli (over-the-counter): 60 mg three times daily with meals
XENDOS, the largest orlistat trial (Torgerson et al., Diabetes Care, 2004) at 4 years:
- Average weight loss: 5.8 kg with orlistat vs 3.0 kg with placebo
- Roughly 3 to 4% body weight loss vs placebo
- 21% reduction in progression to type 2 diabetes
Side effects are predominantly GI and reflect the mechanism: oily stools, fecal urgency, fecal incontinence, oily spotting, increased flatulence with discharge, and decreased absorption of fat-soluble vitamins (A, D, E, K). The GI effects are most pronounced when the patient eats high-fat meals on the medication.
Orlistat is the only OTC weight-loss option (in 60 mg form) and is the only one usable for years without a 12-week limit. It is much less weight-effective than the other prescription options.
Oral semaglutide (Rybelsus)
Rybelsus is the same semaglutide molecule as Ozempic and Wegovy, formulated as an oral tablet with an absorption enhancer (SNAC, salcaprozic acid).
Doses: 3 mg, 7 mg, 14 mg once daily, taken on an empty stomach with at most 4 oz of water and at least 30 minutes before any food, drink, or other oral medication.
Oral semaglutide is FDA-approved for type 2 diabetes only. Off-label use for weight loss in non-diabetic adults occurs but is less common than off-label injectable Ozempic.
PIONEER trial program data (Aroda et al., Lancet Diabetes Endocrinol, 2019) at 26 to 52 weeks:
- Average weight loss at 14 mg: about 4 kg, roughly 4% of baseline body weight
- A1C reduction: 1.0 to 1.4 percentage points
The weight loss with oral semaglutide is meaningfully smaller than with injectable semaglutide, mainly because the 14 mg oral dose corresponds to only about 1 mg of injectable equivalent in plasma exposure due to lower bioavailability. A higher-dose oral semaglutide is in development.
Why injectable GLP-1s outperform every pill
To put oral medication in context, here is how the strongest oral options compare with the leading injectable medications.
| Medication | Type | Avg weight loss at 1 year |
|---|---|---|
| Tirzepatide (Zepbound) 15 mg | Weekly injection | 22.5% |
| Semaglutide (Wegovy) 2.4 mg | Weekly injection | 14.9% |
| Liraglutide (Saxenda) 3.0 mg | Daily injection | 8.4% |
| Phentermine/topiramate (Qsymia) 15/92 mg | Daily oral | 9 to 11% |
| Naltrexone/bupropion (Contrave) 32/360 mg | Daily oral | 5 to 9% |
| Orlistat (Xenical) 120 mg | Daily oral | 3 to 4% |
| Phentermine (Adipex-P) 37.5 mg | Daily oral | 4 to 6% (12 weeks) |
| Oral semaglutide (Rybelsus) 14 mg | Daily oral | About 4% |
Sources: SURMOUNT-1 (Jastreboff et al., N Engl J Med, 2022); STEP-1 (Wilding et al., N Engl J Med, 2021); SCALE Obesity (Pi-Sunyer et al., N Engl J Med, 2015); CONQUER (Gadde et al., Lancet, 2011); COR-I (Greenway et al., Lancet, 2010); XENDOS (Torgerson et al., Diabetes Care, 2004); PIONEER trial program.
Tirzepatide (an injectable, not a pill) currently produces the largest weight loss of any FDA-approved obesity medication. Semaglutide injectable comes second. Among pills, Qsymia leads. The gap between the strongest pill and the strongest injection is substantial.
This is why most patients who want maximum weight loss end up on an injectable rather than a pill. For patients who can't or won't inject, Qsymia is the most weight-effective oral choice currently available.
How to compare strength fairly
A few caveats worth flagging when comparing weight-loss medications.
Trial duration matters. Phentermine alone is studied at 12 to 24 weeks. The other medications are studied at 56 to 72 weeks. If you compare 12-week phentermine to 56-week Qsymia, you're comparing different time points.
Baseline weight matters. Trials enrolled patients with BMI roughly 30 to 45. Patients with lower or higher starting BMIs may have different responses.
Lifestyle co-intervention matters. Most large trials paired the medication with a moderate calorie deficit (500 kcal/day) and counseled exercise. Real-world weight loss without lifestyle changes is typically less.
Discontinuation rates matter. A medication with a 50% average weight loss but 90% discontinuation produces less real-world benefit than one with a 30% average loss but 95% retention.
Individual variation matters. Within any trial arm, the standard deviation of weight loss is large. Some patients lose nothing; some lose 30% or more. The "average" is a starting point, not a destination.
The cleanest single comparison is "average percent body weight loss at 56 weeks at the maximum approved dose vs placebo, in randomized trials." On that metric, the rankings above are accurate as of April 2026.
Side effects and contraindications by drug
| Medication | Top 3 side effects | Major contraindications |
|---|---|---|
| Qsymia | Paresthesia, dizziness, constipation | Pregnancy, glaucoma, hyperthyroidism |
| Contrave | Nausea, constipation, headache | Seizures, eating disorders, chronic opioids |
| Phentermine | Insomnia, dry mouth, palpitations | CV disease, hypertension, glaucoma |
| Orlistat | Oily stool, fecal urgency, fat-soluble vitamin loss | Chronic malabsorption, cholestasis |
| Rybelsus | Nausea, diarrhea, vomiting | MTC history, MEN 2 |
Each medication carries its own risk profile. The decision should weigh weight-loss efficacy against the patient's other medical conditions and risk tolerance. Working with a provider who can match the right drug to the right patient is the typical path.
Who is and isn't a candidate for the stronger options
Most weight-loss medications follow the same general label criteria: BMI of 30+ or BMI of 27+ with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea).
Likely candidate for Qsymia or Contrave:
- Adults meeting BMI criteria above
- Tried lifestyle changes without sufficient weight loss
- No major contraindications to the specific drug
- Willing to commit to long-term medication use
Not a candidate for Qsymia:
- Pregnant or planning pregnancy near-term
- History of glaucoma
- Hyperthyroidism
- Recent MAOI use
- Severe renal impairment
Not a candidate for Contrave:
- Seizure history
- Bulimia or anorexia, current or past
- Chronic opioid use
- Uncontrolled hypertension
Not a candidate for any obesity pharmacotherapy:
- Pregnancy
- Severe untreated psychiatric illness
- Active substance use disorders involving stimulants
For patients without contraindications who want maximum weight loss, a conversation about whether an injectable GLP-1 is the right starting point makes sense, since the magnitude of effect is meaningfully larger than any pill.
FAQ
What is the strongest weight loss prescription pill? Phentermine/topiramate (Qsymia) at the 15 mg/92 mg dose is the strongest oral prescription weight-loss medication, producing 9 to 11% body-weight loss over 56 weeks in trials. Injectable medications (Wegovy, Zepbound) outperform every pill but require weekly subcutaneous injection.
Is Qsymia stronger than Contrave? Yes. In published trials, Qsymia produces an average of 9 to 11% body-weight loss at the top dose, while Contrave produces 5 to 9%. Qsymia gets a larger proportion of patients past the 10% threshold (47% vs ~25%).
What about Ozempic in pill form? Oral semaglutide is sold as Rybelsus, FDA-approved for type 2 diabetes at doses up to 14 mg daily. Off-label weight loss is about 4% on average, less than the injectable forms because of lower bioavailability. A higher-dose oral semaglutide is in development.
Is phentermine the strongest weight-loss pill? Phentermine alone produces 4 to 6% weight loss in 12 weeks, which is faster but lower magnitude than Qsymia or Contrave at 56 weeks. Phentermine is FDA-approved only for short-term use (up to 12 weeks under the label), which limits its long-term role.
Are weight-loss pills safe long term? Some are safer than others for long-term use. Orlistat has the longest published continuous-use data (4 years in XENDOS). Qsymia, Contrave, and Wegovy all have year-long randomized data and longer post-marketing data. Phentermine alone is labeled for short-term use only.
Can I get a prescription weight-loss pill without a doctor? No. All FDA-approved prescription weight-loss medications require a licensed provider's prescription. The only OTC option is low-dose orlistat (Alli, 60 mg). Online telehealth platforms can provide a prescriber visit but the medication still requires a prescription.
How much weight do you lose on Qsymia? At the top 15 mg/92 mg dose, average weight loss is 9 to 11% of baseline body weight at 56 weeks. About 47% of patients achieve at least 10% loss. Individual results vary widely based on adherence, lifestyle, and baseline characteristics.
Is Contrave a controlled substance? No. Bupropion is not a controlled substance, and naltrexone is not either. Contrave can be prescribed via standard prescription without DEA scheduling restrictions.
Is phentermine a controlled substance? Yes. Phentermine is a Schedule IV controlled substance under the federal Controlled Substances Act. Prescriptions are limited in duration and quantity.
Does Wegovy count as a pill? No. Wegovy is a once-weekly subcutaneous injection. It is the most weight-effective FDA-approved medication after tirzepatide (Zepbound), but it is not a pill.
What's the difference between Qsymia and phentermine? Phentermine alone is a single-agent appetite suppressant. Qsymia combines phentermine with topiramate in a fixed-dose extended-release capsule, which increases efficacy and allows long-term use. The combination produces about double the weight loss of phentermine alone over a year.
Which weight-loss pill works fastest? Phentermine works fastest in the short term, with appetite suppression noticeable within days and meaningful weight loss within 2 to 4 weeks. The faster onset reflects its sympathomimetic mechanism. Qsymia and Contrave have slower titration and slower visible weight loss.
Sources
- Gadde KM, et al. CONQUER: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults. Lancet. 2011;377:1341-1352.
- Allison DB, et al. EQUIP: Controlled-release phentermine/topiramate in severely obese adults. Obesity. 2012;20:330-342.
- Greenway FL, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I). Lancet. 2010;376:595-605.
- Apovian CM, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR (COR-II). Obesity. 2013;21:935-943.
- Torgerson JS, et al. XENDOS: XENical in the prevention of diabetes in obese subjects. Diabetes Care. 2004;27:155-161.
- Jastreboff AM, et al. SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
- Wilding JPH, et al. STEP-1: Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
- Pi-Sunyer X, et al. SCALE Obesity and Prediabetes Trial: A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22.
- Aroda VR, et al. PIONEER 4: oral semaglutide vs liraglutide in patients with type 2 diabetes. Lancet. 2019;394:39-50.
- Qsymia Prescribing Information, Vivus LLC, current revision.
- Contrave Prescribing Information, Currax Pharmaceuticals, current revision.
- American Association of Clinical Endocrinology Obesity Pharmacotherapy Guidelines. Endocrine Practice. 2022.
- Khera R, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424-2434.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Qsymia is a registered trademark of Vivus LLC. Contrave is a registered trademark of Currax Pharmaceuticals. Adipex-P and Lomaira are trademarks of their respective owners. Xenical and Alli are trademarks of Roche and GlaxoSmithKline respectively. Rybelsus, Ozempic, Wegovy, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Related FormBlends Guides
These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:
- What Is the Strongest Weight Loss Prescription Pill? The 2026 Evidence-Based Ranking
- Oral Semaglutide for Weight Loss Complete Guide
- Oral Semaglutide For Weight Loss: Complete Guide 2026
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →